Avexitide
Phase 3Peptide
Avexitide is one of 42 small molecule programs targeting Hypoglycemia. It is currently in Phase 3.
2
Indications
2
Total Trials
1
Active Trials
41
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
77 competitors in Hypoglycemia
#DrugCompanyPhaseTrials
1Narcan
SScienture
Approved
Glucagon
XXeris Pharmaceuticals
Phase 3
Ilaris
NovartisPhase 3
Zegalogue
Zealand PharmaPhase 3
Jardiance
Boehringer IngelheimPhase 3
Sandostatin
Sun PharmaPhase 3
Glibenclamide
Novo NordiskPhase 3
Glucobay
BayerApproved
Elavil
AstraZenecaPhase 2
MS Contin
Merck & Co.Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Hyperinsulinemic Hypoglycemia1 trial
Avexitide Safety and Efficacy to Treat Acquired Hyperinsulinemic Hypoglycemia
Completed·—·Phase 2·NCT04652479·25 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Avexitide. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Peptide[2]
- Highest Phase
- Phase 3[1]
- Company
- AAmylyx Pharmaceuticals Inc.